Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-428 in advanced solid tumors
NCT02955251Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of ABBV-428 in solid tumor (advanced stage) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events up to 2 years, Recommended Phase 2 Dose at 28 days and 5 more. Started Nov 2016; status: completed.
02
Drugs
ABBV-428
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02955251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955251.